Description: Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company uses its proprietary technology to develop its products comprising Capture and Contain, a containment barrier against a range of allergen particulates and viruses; and Trap and Target for nasal delivery of active pharmaceutical ingredients. It develops PL-14, a nasal allergies blocker; PL-15 for COVID-19; and PL-16 for influenza. The company was incorporated in 2005 is headquartered in Ra'anana, Israel.
Home Page: www.polyrizon-biotech.com
5 Ha-Tidhar Street
Ra'anana,
4366507
Israel
Phone:
972 5 5433 5665
Officers
| Name | Title |
|---|---|
| Mr. Tomer Izraeli | Founder, CEO & Director |
| Mr. Nir Ben Yosef | Chief Financial Officer |
| Dr. Eyal S. Ron Ph.D. | Chief Technology Officer |
| Ms. Daphna Avital | Chief People Officer |
| Dr. Tidhar Turgeman | Chief R&D Officer |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2024-10-29 |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |